Podcasts about Progression

Research Identifies Link to Oral Cancer Progression, Associated Pain, and Specific Calcium ChannelBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-identifies-link-to-oral-cancer-progression-associated-pain-and-specific-calcium/Need CE? Start earning CE credits today at ⁠https://rdh.tv/ce⁠ Get daily dental hygiene articles at ⁠https://www.todaysrdh.com⁠ Follow Today's RDH on Facebook: ⁠https://www.facebook.com/TodaysRDH/⁠Follow Kara RDH on Facebook: ⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠Follow Kara RDH on Instagram: ⁠https://www.instagram.com/kara_rdh/⁠

In episode 310 of the podcast, we're joined by Daryl Taberski (vocals) of Snapcase.We dig into the 90s Buffalo scene, the formation of the band, signing with Victory Records, touring in the 90s, records (Progression, Designs, etc), the changing musical landscape over the years, what's next for the band, and everything in between. This is a classic past to present Podioslave special. Shouts to Daryl for being an all-time guest of the pod.Keep an eye out out for the upcoming Snapcase documentary (IG: @snapcaselegacy)Follow Snapcase on IG: @snapcasebandPhoto Credit: Greg Flack (IG: @xgregflackx)Podcast theme performed by Trawl. Follow them here:WebIG/X/TikTok: @trawlbandWe'd love for everyone to hear this episode! Support the Podioslave family by rating, subscribing, sharing, storying, tweeting, etc — you get the vibe. Peace, love, and PodioslaveCheck us out here:WebIG/Threads/X/TikTok: @PodioslaveYoutubeEmail: Podioslavepodcast@gmail.com

Does nutrition matter when you are facing prostate cancer? In this episode, Dr. Stephen Petteruti lays out a practical, data-driven framework for prostate cancer nutrition, cancer progression, metabolic health, PSA management, and longevity medicine. Portion control, feeding timing, insulin sensitivity, hemoglobin A1C, triglycerides, and visceral fat all matter. He explains why structured eating patterns, net carbohydrate awareness, and metabolic control often outweigh trendy diet labels.Dr. Stephen also addresses high-risk dietary exposures that many overlook: processed meats and nitrites, sodium benzoate, artificial sweeteners and weight gain signals, petroleum-based food dyes, and chronic high-sugar intake in insulin-resistant individuals.Instead of extreme restriction, he advocates strategic elimination of the biggest carcinogenic inputs while preserving quality of life.If you care about longevity, cancer prevention, and metabolic optimization, spend time with this episode of Best Diet for Prostate Cancer | What Actually Matters for Cancer Progression.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Learn more: https://www.drstephenpetteruti.com/Learn more: https://www.intellectualmedicine.com/Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠Subscribe to Intellectual Medicine on:Apple Podcast: https://tinyurl.com/DrPetterutiApplePodcastSpotify: https://tinyurl.com/DrPetterutiSpotifyPodcastDisclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Sale announcement: 25% OFF ALL TTM PROGRAMS — sale ends Feb. 22. If you're serious about improving performance, now is the time to start. Today's Q&A topics:03:18 - Subs for sled push work?06:50 - Min effective dose of conditioning when trying to bulk10:59 - Should you stay in SFAS prep mode year-round?15:24 - Best times of year to go to selection19:33 - Tips for sleep health when working overnight22:01 - Skipping test/deload weeks pre-SFAS24:54 - Prepping for the Norwegian march 25:40 - Is it effective to train biceps + triceps every day for bigger arms?29:10 - Considerations for training late in the evening 34:29 - Sub for 400 meter repeats if no access to a track36:29 - Things to consider with sand beach runs38:19 - How to progress ruck weight and time41:26 - How to maintain motivation for the Q when injured—Questions? Look for bi-weekly Q&A on my stories. I'll answer your questions on IG and here on the podcast.—New Selection Prep Program: Ruck | Run | Lift New Hybrid Program: Jacked Gazelle 3.0Ebook: SOF Selection Recovery & Nutrition Guide—TrainHeroic Team Subscription: T-850 Rebuilt (try a week for free!)—PDF programs2 & 5 Mile Run Program - run improvement program w/ strength workKickstart- beginner/garage gym friendlyTime Crunch- Workouts for those short on timeHypertrophy- intermediate/advancedJacked Gazelle- Hybrid athleteJacked Gazelle 2.0 - Hybrid athleteSFAS Prep- Special forces train-upRuck | Run | Lift - Selection Prep—Spoken Supplements: Code terminator_trainingCwench supplements: Code terminator_training—Let's connect:Newsletter Sign UpIG: terminator_trainingYoutube: Terminator Training Methodwebsite: terminatortraining.comSubstack

Suite à l'attaque au manoir, Pansy se fait donner du véritasérum et tente de résister tant bien que mal. Le quartier général de l'Ordre du Phénix devient plus important maintenant que les jumeaux, Ginny, Luna, Bill et Fleur y sont. Malheureusement, Arthur, Molly et Percy ont été emprisonnés à Azkaban. Bellatrix visite la tombe des Malfoy... et après toutes ces aventures, l'Ordre renaît enfin de ses cendres. Mais les Malfoy sont une menace qui plane sur cette renaissance...Progression de lecture: 60%Fanfiction en anglaisFanfiction en françaisPatreonBuy me a CoffeeSpotifyLogo par Sabrina CayerInstagram: ⁠@cozywithbrinaMusique: The Streets of Baerlon, par Ivan Duch / Dwarven King's Tomb (Ambient), par Ivan Duch (https://ivanduch.com)

Le sujet fort de l'actualité foot du jour vu par Jérôme Rothen et la Dream Team.

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

On episode 734 of 40+ Fitness Podcast, we dive into the world of hybrid athleticism with Alex Vieira, renowned coach, educator, and author of The Ultimate Hybrid Athlete: A Definitive Guide to Achieving Peak Athleticism Across All Disciplines. Hosted by Allan, this episode explores what it really means to be a "hybrid athlete"—balancing strength, endurance, and overall resilience no matter your age. Alex shares his journey from clinical research to coaching more than 1,000 athletes, and explains how anyone—regardless of body type or background—can train to be both strong and enduring. You'll learn about eliminating "junk volume" in your workouts, the true meaning of progressive overload, and how to periodize your training when you're balancing multiple athletic goals. Plus, Alex introduces the RAMP warm-up system, and offers practical strategies for staying healthy, fit, and mentally sharp well into your 40s and beyond. Time Stamps: 05:38 Embracing Growth Beyond Identity 07:21 Training with Intent 10:17 Progressive Overload Simplified 15:06 Hybrid Training and Progression 18:43 Steps to Optimize Workout Prep 22:56 70/30 Diet Planning Approach 23:52 Balance Life and Sharpen Mind https://completehumanperformance.com  

Fr. Dan Reehil uses today's first reading to explain the nature and progression of sin.Radio Maria is a 100% listener supported radio station. If this broadcast has touched your life, please consider donating at https://rmusa.civi-go.net/donateStream live episodes of Battle Ready with Fr. Dan Reehil at https://radiomaria.us/ at 9:00 am cst or tune in on radio in Louisiana (580 AM Alexandria, 1360 AM New Iberia, 89.7 FM Natchitoches, 91.1 FM Lake Charles) in Ohio (1600 AM Springfield, 88.7 FM Anna, 103.3 Enon/Dayton) in Mississippi (88.1 FM D'Iberville/Biloxi) in Florida (91.9 Hammocks/Miami) in Pennsylvania (88.1 FM Hollidaysburg/Altoona) in Texas (1250 AM Port Arthur) in Wisconsin (91.3 FM Peshtigo), 1280 AM Columbia, TN (98.9 FM Columbia, TN)Download the Radio Maria Play app to any smart device:Android: https://play.google.com/store/apps/details?id=com.radiomaria.v3&hl=en_US&gl=US&pli=1iOS: https://apps.apple.com/us/app/radio-maria-play/id848153139 

Sean tells Don and Sam about getting sober at 15, never having had a legal drink. Sean's early exposure to AA was through a rehab. He remembers going to a meeting which was just the leader and the other folks from his rehab. He was impressed when the leader said he was serving in the role because he didn't want to drink. There's a History Snippet with Mily, and Martina shares her love for Grapevine.While we provide the podcast at no charge, we do have expenses. Grapevine is the only AA entity that does not accept direct contributions, so to support the AA Grapevine Podcast, please subscribe to Grapevine Magazine in print, online, or on the Grapevine app. You can also provide a subscription to someone in need through our "Carry the Message" program or purchase books or other items at aagrapevine.org/storeYou can email us at podcast@aagrapevine.org. To record an Ask-It-Basket question or a recovery-related joke, call 212-870-3418 or email a voice recording to podcast@aagrapevine.org

Dr. Greg Cooper and Dr. David G. Coughlin discuss the role of αSyn-SAAs in diagnosing DBL and their relationship with Alzheimer's disease biomarkers.  Show citation: Coughlin DG, Jain L, Khrestian M, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression. Neurology. 2025;105(12):e214346. doi:10.1212/WNL.0000000000214346 Show transcript:  Dr. Greg Cooper: Hi, this is Dr. Greg Cooper. I just finished interviewing Dr. David Coughlin for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. David Coughlin: The main points of this paper in my mind is that α-Synuclein seed amplification assays from cerebrospinal fluid samples is useful in confirming the presence of synuclein pathology in people with clinically suspected dementia with Lewy bodies. But also that, for people who have synuclein positivity, that the presence of Alzheimer's disease mixed pathology is associated with a worse cognitive progression over time. Dr. Greg Cooper: Thank you Dr. Coughlin, for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology, CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers in Dementia with Lewy Bodies. Thank you.

IgA nephropathy remains the most common immune-mediated glomerular disease worldwide — and up to 50% of patients may progress to kidney failure within a decade.

In this detailed conversation, Alex Harvey discusses his recent impressive half marathon in Japan, the skepticism around his progression, and his transparent use of Strava to share his full training. Alex breaks down his early marathon times and steady improvement through consistent training. He covers marathon challenges (fueling and getting intensity right), how business and family life fits around training, and his aspirations heading into Tokyo Marathon. He also shares why racing without a strict time goal can be valuable, plus how context-specific training has helped him progress. We also get into his preference for training alone, keeping training efficient, and his approach to diet - along with why he largely avoids strength training and cross training. Follow Alex Instagram: https://www.instagram.com/alexxharvey/ Strava: https://www.strava.com/athletes/46089368/ Work With / Follow Matt Coaching: https://www.sweatelitecoaching.com/coaching-2026 Shareholders Club / Private Feed: https://www.sweatelite.co/shareholders Instagram: https://www.instagram.com/mattinglisfox/ Strava: https://www.strava.com/athletes/6248359 Contact: matt@sweatelite.co Topics 00:00 Introduction and Recent Achievements 00:10 Addressing Skepticism and Progression 02:42 Early Running Experiences 03:51 Transition to Serious Training 05:05 High School and Early Twenties 07:35 Inspiration to Start Running 09:38 Recent Race Highlights 12:59 Training Philosophy and Volume 17:48 Training Alone and Flexibility 19:42 Speed Work and Coaching 24:28 Long Runs and Marathon Preparation 25:03 Training in the Heat: Adapting to Queensland's Climate 26:02 Key Training Sessions: Building Endurance and Speed 27:09 Mental Strategies for Pacing and Performance 30:21 Fueling Challenges and Solutions 33:34 Balancing Life: Business, Family, and Running 38:28 Speed and Distance: Exploring Potential and Preferences 41:59 Diet and Weight Management for Optimal Performance 44:45 Cross Training and Strength Training Insights 47:16 Final Thoughts and Where to Follow

Host: Yuval Zabar, MD Guest: Michelle Mielke, PhD Guest: Henrik Zetterberg, MD, PhD For the latest insights on tau and neurodegeneration biomarkers in Alzheimer's disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade', the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg. To learn more about tau in Alzheimer's disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

On this episode, Gaetan (founder of Colombia eFoil) and Justin Chait (experienced eFoil coach and instructor) join us to talk about the building and running one of the premier e-foiling destinations in the Caribbean: a multi-location flight school and immersive retreat experience on the stunning Isla Barú peninsula near Cartagena, Colombia.They share how Gaetan turned his passion for water sports—and his first e-foil flight (with Justin as his original instructor)—into a thriving business launched exactly two years ago, now operating out of luxury resorts including Aura Hotel Barú (the flagship spot with beachfront access), Sofitel Barú, and Hotel Las Islas.Episode Highlights:- The paradise-like conditions that make Barú an ideal e-foiling hub: flat, protected bay waters with mangroves, kilometers of glassy riding, warm 30°C+ water, consistent year-round weather (rare closures), and easy access to open ocean and nearby islands like Islas del Rosario for long-distance adventures- How the operation works: three fully equipped bases with rescue boats, on-site charging, instructor-led boat coaching for safety and video feedback, premium service (boards prepped and rinsed for you), and the ability to ride from sunrise to sunset in board shorts- Justin's coaching philosophy: breaking down fundamentals for riders of all levels, re-teaching body position and throttle control to build safer, more efficient technique that reduces fatigue and extends battery life—turning intermediates into advanced riders and helping beginners fly in days- The famous 6-day eFoil retreats: beginner-friendly versions with open-sea crossings and island lunches by day 3; advanced/pro camps featuring daily drone video analysis, lap-time courses, wave riding, racing drills, 4–5 hours of riding per day, and group energy that pushes everyone's limits- Progression stories: students winning divisions at major events like Dubai after training there, couples where non-riding partners end up hooked, riders from 20 to 69 years old shredding (including 69-year-old wing-breeching legends), and a high return rate (~50%) of participants who come back for multiple retreats- Gear & practical details: primarily using Fliteboard (as official distributor in Colombia), options to bring your own setup or rent, testing different wings/shims during retreats, what to pack (sunscreen, rash guard, hat, sunglasses—no wetsuit needed), and full all-inclusive logistics from airport pickup to excursions, diving, gourmet meals (fresh snook, octopus, tropical fruits), and epic group dinners/parties- Why Colombia (especially Cartagena/Barú) is a game-changer for e-foiling: safe, tourist-friendly area with world-class resorts, incredible value, crystal-clear waters, wildlife, and a welcoming vibe that builds lasting rider friendships and communitiesIf you're dreaming of learning e-foiling in perfect warm flat water, accelerating your skills with world-class coaching, chasing long-distance island runs, or simply enjoying a luxury Caribbean foiling vacation—this conversation is loaded with inspiration, real-world insights, and pure stoke.Check out Colombia eFoil at colombiaefoil.com (retreat details at www.colombiaefoil.com/efoil-retreat), reach them via WhatsApp (+57 304 315 1220), email (booking@colombiaefoil.com), or Instagram @colombia_efoil. They're also highly rated on TripAdvisor and Google with hundreds of 5-star reviews.Listen now and start planning your own e-foil escape to Cartagena & Barú!

Exercise can ease Parkinson's symptoms — but can it also slow the disease itself?In this Being Patient Live Talk, Northwestern University researcher Daniel Corcos, PhD breaks down the science behind high-intensity aerobic exercise and why his team is putting it to the test in a major Phase 3 clinical trial (SPARX3). SPARX3 is designed to examine whether exercise intensity can influence Parkinson's progression, especially for people who are newly diagnosed and not yet taking Parkinson's medication.Corcos, a professor in Northwestern's Department of Physical Therapy and Human Movement Sciences, shares what research has already taught us about exercise and Parkinson's — and what we still need to prove. He also lays out a practical, four-part “exercise prescription” you can use as a framework:✅ Aerobic training✅ Resistance/strength work✅ Flexibility✅ Balance + neuromotor trainingYou'll also learn how SPARX3 will follow 370 participants over two years, comparing moderate- vs. high-intensity treadmill training and tracking changes in symptoms and brain imaging to explore whether higher intensity is linked to slower progression.Hosted by: Deborah Kan, Founder of Being Patient--- Subscribe for more Live Talks and brain health reporting:https://www.beingpatient.com/Follow Being Patient:Twitter/X:   / being_patient  Instagram:   / beingpatientvoices  Facebook:   / beingpatientalzheimers  LinkedIn:   / being-patient  Watch more Live Talks:https://beingpatient.com/live-talks/Being Patient is an editorially independent journalism outlet covering brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series, founder and former Wall Street Journal editor Deborah Kan interviews brain health experts and people living with dementia.#parkinsonsdisease #Exercise #SPARX3 #BrainHealth #Neurology #ParkinsonsResearch #Fitness #MovementDisorder #BeingPatient

Send a textWelcome Back to The Beyond Condition PodcastJoin me for a solo episode where I share an important message with our community: progress is achievable for everyone, but understanding the toll it takes on you is crucial.‘Is Obsession Holding You Back From More Progression?'Each of us has our own unique journey, complete with past experiences and future aspirations. Several factors might influence your perception of how ‘obsessed' we should be to make progress. My aim is to provide insights that will enhance your understanding of the pillars of progression.Topics Discussed:Monitoring ProgressionSelf-AwarenessUnderstanding Your Own Belief SystemCommunication with Your CoachI hope you enjoy this episode, and as always, thank you for your unwavering support.S xWatch it here: https://youtu.be/EdcHClGJN7AFind Sarah on Instagram: @sarahparker_bb THE ULTIMATE SHOW DAY GUIDE E-BOOK: Purchase here Beyond Condition Coaching Application: Click here

Personal Flow and Attachment Soo Kim expressed a feeling of being on the "verge of something". Jevon Perra commented that Soo Kim was doing great with "not attaching to any outcome and just flowing non-judgmentally," which Jevon Perra admitted they struggle with, though they are aware of their attachments. They agreed that the unawareness of one's "craziness" is what causes trouble.Judgment and Sincerity Jevon Perra stated that they constantly have judgments, including about people who are "happy nice," like their Mormon friends, where they don't perceive sincerity. Soo Kim related to the judgment of insincerity, citing it as a major reason for a "rupture with Leila," because they judged her actions as insincere and fake. Jevon Perra agreed that having the data to be "right about my perceptions" is not the ultimate goal because their perceptions and best-case scenarios do not lead to ultimate happiness or peace.Contentment as the Highest State Jevon Perra asserted that the pursuit of achievement and accomplishment does not bring unending happiness and bliss, noting that past moments of having everything only brought momentary satisfaction. They suggested that the "other game" is to simply be content, which they considered "probably the highest state," because if one is content, their apparent energetic state does not matter as much.Illusion of the Singular Self and Happiness Set Point Soo Kim discussed the "illusion of the singular self," stating that even within a personality construct, there are multiple aspects, and the matter is which one one attaches to. Jevon Perra referenced a psychology book, The How of Happy, which suggests that most of one's happiness is set by genetics and other propensities, but about 30% comes from choices made, specifically one's speech and thoughts.The Meaning of Seriousness When asked where they fall on the happiness scale, Jevon Perra described Soo Kim as a "princess warrior type," serious about what is real and true, which Jevon Perra relates to. Jevon Perra defined being serious as meaning "life and death," explaining that to be serious is to stop playing, believe something will kill you, and stop being loose, unguarded, and oneself. They also related seriousness to suffering, where one stops "trusting God" and takes matters into their own hands, leading to suffering.The Enneagram Type Three Racket Jevon Perra shared that as an Enneagram Type Three, they are a performer who struggles to know what is truly them, losing themselves in their performances because they prioritize achievement. They explained that a "racket" is a game played to hide the "real business," drawing an analogy to a butcher shop fronting an alcohol operation during prohibition. Jevon Perra stated that their current "racket" involves engaging in human suffering to be relatable to others, but they get lost in the pain of the character they are playing.Connection versus Attachment Soo Kim questioned the sincerity of relating to people without "getting sucked in," calling it a form of insincerity and faking. Jevon Perra made a distinction between trying to relate and trying to connect, emphasizing that needing to connect is also an attachment. Jevon Perra described extreme attachment as the "needy" individual whose outward show of love is experienced as taking, not giving, because they are trying to "vampire" or suck life from the other.The Origin of Sincerity Discussing sincerity, Jevon Perra provided the etymology of the word, explaining that it is Latin for "without wax," originating from the practice of repairing broken marble statues with wax and dust. To be sincere means not hiding brokenness or what one does not want others to see; it means being transparent. Jevon Perra contrasted this with insincere interactions, such as someone being overly nice, suggesting that something is being hidden.The Progression of Relationships and Sincerity Jevon Perra discussed that normal human interactions are permission-based, with gradual sharing of more personal or "sketchy" information. They noted that always presenting only the cordial side is insincere, and relationships must progress, or the lack of progression signals an issue. If cracks are not shown willingly, Jevon Perra cautioned that they will be revealed through pressure or conflict, which is hurtful.Childhood Dynamics and Emotional Triggers Soo Kim related Jevon Perra's observations about insincerity to their own experience of being triggered and wanting to tell others how they were not hearing them, which mirrors a childhood dynamic where they learned defense mechanisms like taking things seriously to feel safe. Soo Kim felt their mother needed them to behave a certain way to feel like a "good mom," leading to a dynamic where they felt unable to be themself.The Attachment to Outcomes Jevon Perra shared their current personal lesson, which is the triggering belief that they "have to take care of people," specifically their family. This belief leads to an attachment to assuring outcomes, such as having "enough money" or ensuring their kids are not hurt, which causes incredible unrest and suffering because they try to love and attack their family at the same time by preventing harm. Jevon Perra identified the solution as releasing the attachment to outcomes, which they believe are already set by a script and soul contracts.Contentment through Trust and Release Jevon Perra concluded that the stress of trying to assure outcomes has no bearing on what happens, only providing the experience of suffering instead of contentment. True contentment comes from "trusting God," which means realizing that everything is perception. They explained that every perception creates a separate identity, which is the world of attachment and suffering.Maya and Lowering Consciousness Jevon Perra introduced the concept of "Maya" as the energy of separation that draws consciousness to lower its resonance to operate in the "super low frequency called personality called the body". They observed that the more aware they become, the more painful it is to be "a little bit off," explaining that their awareness makes them suffer more, not because awareness is negative, but because the subtle disturbance is now enough to bother them.The Princess and the Pea Parable Jevon Perra used the fairy tale of "The Princess and the Pea" to illustrate that spiritual growth makes one more sensitive to subtle disturbances, requiring less and less to bother them. They stated that the spiritual game is one of "less and less" and "letting go game, not a grab more game," leading to the realization that one is already content.The Selfish Gain of Sincerity Jevon Perra stated that the "true work" is realizing one is working for themself, as their personality's selfish gains will not bring ultimate contentment or peace. They observed that both the rich and the poor can be happy, and happiness comes from "stopping of the searching".Releasing Fear and Insanity Jevon Perra spoke about their current situation of quitting a job and not having an income, which triggers their fear that their family will "die" and it is their fault. They shared the experience of releasing attachments while on vacation, which instantly brought freedom and contentment to their life. They concluded that their ultimate insanity is thinking they are the body and personality that wants accomplishments, and the greatest enemy to the separate identity is love, because love is "all inclusive and abundant".Managing Seriousness and Awareness Jevon Perra discussed how unaware they are of many things, using the example of their watch light in sleep mode. They asked Soo Kim if their suggestion to "tread lightly" and "be innocent of the danger" was meant to combat an overly serious nature. Soo Kim confirmed that their goal was to combat their "over seriousness".Embracing Goofiness and Non-Attachment Jevon Perra shared that they sometimes go from being overly serious to being "overly goofy," which they find fun and a "light life". They concluded that life is not so serious because "you can't die," and if they lose their accomplishments, they asserted, "I'm not my accomplishments".

Arknights: Endfield is not a normal anime gacha.Yes, it looks like Genshin.Yes, it uses Honkai-style progression and banners.But the real core is something much riskier: factory automation inspired by Factorio and Satisfactory, deeply embedded into progression, crafting, power, and economy.This is a high-budget, niche bet. And it's already showing both explosive upside and structural risk.Get our MERCH NOW: 25gamers.com/shop--------------------------------------PVX Partners offers non-dilutive funding for game developers.Go to: https://pvxpartners.com/They can help you access the most effective form of growth capital once you have the metrics to back it.- Scale fast- Keep your shares- Drawdown only as needed- Have PvX take downside risk alongside you+ Work with a team entirely made up of ex-gaming operators and investors---------------------------------------For an ever-growing number of game developers, this means that now is the perfect time to invest in monetizing direct-to-consumer at scale.Our sponsor FastSpring:Has delivered D2C at scale for over 20 yearsThey power top mobile publishers around the worldLaunch a new webstore, replace an existing D2C vendor, or add a redundant D2C vendor at fastspring.gg.---------------------------------------This is no BS gaming podcast 2.5 gamers session. Sharing actionable insights, dropping knowledge from our day-to-day User Acquisition, Game Design, and Ad monetization jobs. We are definitely not discussing the latest industry news, but having so much fun! Let's not forget this is a 4 a.m. conference discussion vibe, so let's not take it too seriously.Panelists: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jakub Remia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠r,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Felix Braberg, Matej Lancaric⁠Podcast: Join our slack channel here: https://join.slack.com/t/two-and-half-gamers/shared_invite/zt-2um8eguhf-c~H9idcxM271mnPzdWbipgChapters00:00 — Why Arknights: Endfield matters01:20 — What kind of game this actually is03:10 — Open world structure & exploration05:00 — Factory building as the real core07:00 — Power grids, pylons & automation09:30 — Factorio / Satisfactory influence11:40 — Outposts, trading & economy loops13:30 — Characters, teams & combat flow15:10 — Progression systems & crafting17:00 — Gacha structure & monetization logic18:40 — Audience fit: who this is (and isn't) for20:20 — Final verdict & scale risk---------------------------------------Matej LancaricUser Acquisition & Creatives Consultant⁠https://lancaric.meFelix BrabergAd monetization consultant⁠https://www.felixbraberg.comJakub RemiarGame design consultant⁠https://www.linkedin.com/in/jakubremiar---------------------------------------Please share the podcast with your industry friends, dogs & cats. Especially cats! They love it!Hit the Subscribe button on YouTube, Spotify, and Apple!Please share feedback and comments - matej@lancaric.me---------------------------------------If you are interested in getting UA tips every week on Monday, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠lancaric.substack.com⁠⁠⁠⁠⁠⁠ & sign up for the Brutally Honest newsletter by Matej LancaricDo you have UA questions nobody can answer? Ask ⁠⁠⁠⁠⁠⁠⁠⁠Matej AI⁠⁠⁠⁠⁠⁠ - the First UA AI in the gaming industry! https://lancaric.me/matej-ai

This episode features Rich Summers(IG: @rich_somers) a real estate investor managing $90 million in assets and several boutique hotels, and Michael Sartain, a personal branding and marketing expert. The dialogue covers multiple topics including personal branding, social media strategies, sales tactics, dating dynamics, mindset, business scaling, and societal observations. 00:00 - Intro 01:14 - Victim Mentality vs. Ownership 02:40 - Strategies for Social Media Viral Growth 05:34 - The Value of Long Form Content 07:55 - Building a Repeatable Content System 09:34 - Building a Personal Brand for Status 11:26 - Tactics for Progression in Dating 13:39 - Leveraging Team Dynamics for Trust 15:38 - Time Management and Meeting Systems 18:29 - Business Lessons from Industry Leaders 21:08 - Scaling Brands with Paid Advertising 22:59 - Monetizing Podcasts and Yacht Workshops 30:16 - Sales Tactics and Community Revenue 35:37 - Closing Deals and Personalized Content 40:53 - Investing and Scaling Back-End Revenue 46:30 - Fame vs. Influence in Marketing 51:04 - Biological and Strategic Dating Dynamics 58:43 - Evolution, Social Standards, and Economics 01:10:45 - Business Risks of Political Commentary 01:18:06 - Generational Wealth Transfers and Growth ————————————————————

Weekly Kingdom Outlook Episode 225-Daily Prayer As we progress, the progression of prayer will encompass our daily prayers, abiding prayers, and eventually the courtroom atmosphere. I intend to demonstrate the various aspects of prayer during these three weeks as we mature in the Lord and receive greater authority.

durée : 00:11:13 - Le Fil de l'histoire - par : Stéphanie DUNCAN - Durant l'été 1941, rien ne semble pouvoir arrêter la formidable progression des troupes allemandes en Union soviétique. Au bout seulement de trois semaines, elles occupent les pays baltes, la Biélorussie, l'Ukraine et presque toute la Moldavie. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Hour 2 of the Chris Hand Show | Monday 02-09-26 We're diving into the world of the Olympics and the Super Bowl, where patriotism and politics collide. Chris discusses the halftime show, Olympic athletes' statements, and the Save Act. We hear from Olympic skier Hunter Hess, who sparked controversy with his comments on representing America, and figure skater Amber Glenn, who spoke out about the LGBTQ+ community. The conversation also touches on voter ID laws, with a surprising twist from Senator John Fetterman. See omnystudio.com/listener for privacy information.

Caleb Schafer, the Lead Pastor of Redeemer's Church, finishes his series about the New Year being a MOMENT in time that marks WHEN God wants to do a NEW THING-in you, for you, around you, and with you. February 8th, 2026 | 2.8.26 Category: Sensing, Progression, Whisper

The Progression of Alcoholism Alcoholism rarely looks dramatic in the beginning. It usually starts small, normal, social… even fun. Over time the line slowly moves. What once felt optional becomes routine. What once felt controlled becomes unpredictable. And before we know it, alcohol is no longer part of life — it's running life. In today's stream we're breaking down the real progression many of us experienced: • How drinking shifts from social to necessary • The role of tolerance and normalization • The denial that keeps us stuck longer than we planned • When consequences start stacking up • The moment many of us realized something had to change This isn't about judgment — it's about understanding the path so people can recognize it sooner and know recovery is possible at any stage. Jump in the chat and be part of the conversation.

  ⏰

A New Era awaits for the Seahawks? Michael-Shawn Dugar of The Athletic joined Kieran to talk about living out the dream of covering his team all the way to a Super Bowl, Sam Darnold putting the ghosts to bed by doing it when it matters most, and a new Seahawks defense creating their own destiny. Our Radio Row coverage is sponsored by Dunes and Drams

A great fartlek and progressive threshold session to improve your running. Plus, the components that should be part of an effective run program, even though they're not necessarily classified as “run sessions”. Part of this episode is original content, and part of it is a preview of the full episode "Power Rankings - Our top-5 run sessions to improve triathlon running performance" (release date 5th of February 2026). TOPICS COVERED IN THIS EPISODE: Mikael's favourite Fartlek run Jack's descending threshold sessionWhy and how to do strides and hill sprintsWhen is running off the bike a good idea? (Even though a lot of the time it isn't a good idea, and it's probably overused in triathlon)How hilly is a “hilly endurance run”? LEARN MORE ABOUT SCIENTIFIC TRIATHLON: The Scientific Triathlon website is the home of That Triathlon Show and everything else that we doContact us through our contact form or email me directly (note - email/contact form messages get responded to much more quickly than Instagram DMs)Subscribe to our NewsletterFollow us on InstagramLearn more about our coaching, training plans, and training camps. We have something to offer for everybody from beginners to professionals. HOW CAN I SUPPORT THAT TRIATHLON SHOW (FOR FREE)? I really appreciate you reading this and considering helping the show! If you love the show and want to support it to help ensure it sticks around, there are a few very simple things you can do, at no cost other than a minute of your time. Subscribe to the podcast in your podcast app to automatically get all new episodes as they are released.Tell your friends, internet and social media friends, acquaintances and triathlon frenemies about the podcast. Word of mouth is the best way to grow the podcast by far! Rate and review the podcast (ideally five stars of course!) in your podcast app of choice (Spotify and Apple Podcasts are the biggest and most important ones).Share episodes online and on social media. Share your favourite episodes in your Instagram stories, start a discussion about interesting episodes on forums, reference them in your blog or Substack. NordVPN - EXCLUSIVE NordVPN Deal ➼ https://nordvpn.com/TRIATHLONTry it risk-free now with a 30-day money-back guarantee Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On episode 732 of the 40+ Fitness podcast, Coach Allan welcomes strength and fitness legend Dan John to the show, a man whose decades of experience span from elite athletics to coaching and academia. In this episode, Coach Allan, fresh off celebrating his 60th birthday, shares a hard-hitting statistic: only 22% of people actually follow the bare minimum guidelines for strength training. This sets the stage for a powerful conversation on why resistance training isn't just a good idea. It's absolutely vital for anyone over 40 who wants to maintain their health, function, and independence into their later years. Dan John unpacks his concept of "everyday strength," the kind of lasting fitness that lets you handle anything life throws your way, from carrying all your groceries in one trip to chasing after grandkids without missing a beat. Together, Coach Allan and Dan John break down how your focus should evolve with age: building foundational strength in midlife, prioritizing muscle mass, joint mobility, and regular walking as you move through your 50s, 60s, and beyond. Tune in for actionable tips, insights on how to structure your training for the long haul, and the wisdom you need to invest in your future health.   Time Stamps: 04:29 Embracing Strength and Growth 09:15 Strength Retention Over Time 11:20 Everyday Strength and Progression 13:51 Focus on Joint Mobility 18:04 Planning for Independence and Mobility 21:47 Longevity vs. Modern Enhancements 23:53 Pot Belly and Happiness Link 29:22 Walking Routine and Steps 30:43 Why Walking Beats High-Intensity Workouts 35:15 Muscle Beach Memories, 1977 38:39 Steps, Meals, and Caloric Balance 41:44 Embrace the Obvious for Wellness 42:58 Visit Dan John University - https://danjohnuniversity.com 

A few months ago I finally hit a major milestone...After years of putting it off, I finally started taking golf lessons.Jasper, my coach (or "pro" as they say in the golf world), has been helping me develop a proper swing. But being me, I just can't help but look at Jasper through a service design lens.What is he actually selling me? Or better yet: what am I actually buying?Right now, I pay by the hour. That buys me Jasper's time and a bit of grass to practice on. But what if I didn't pay for the service, which is just time well saved, but rather for the outcome?What if Jasper promised to take me from someone who barely knows how to hold a club to being a confident, competent golfer? Because in the end, that's truly the identity shift I'm actually looking for.Just think about how much that proposition would change the dynamics, not just for me, but for Jasper's entire business model. When that offer is on the table, why would I ever settle for a coach selling me "practice time" (a commodity) when I could invest in the transformation I actually desire?This shift toward "transformations" as an economic offering isn't new.It was already described in the industry defining book The Experience Economy back in 1999.We've been lucky enough to have Joe Pine, the book's co-author, on the Show twice before. Now, he's back.It's been 27 years since he published the book that influenced so many of us, and he has just published the long-awaited follow-up titled, you guessed it, The Transformation Economy.In this episode, we sit down to chat about what this shift means for us as service design professionals and what it means for the future of business. I'm fairly certain this is the very first podcast where Joe discusses the new book, so we've got a true exclusive on our hands.So will this be the next chapter for our field? Listen to the episode to find out!As you listen to the conversation, I'd love for you to think about your own projects. Are you designing for "time well spent," or are you ready to guide your customers through a real identity shift?Enjoy the conversation and keep making a positive impact!Be well,~ Marc--- [ 1. GUIDE ] --- 00:00 Welcome to Episode 24604:45 Why the book is still relevant06:15 Progression of Economic Value11:00 Defining economic offerings13:00 Birth of the Transformation Economy17:30 Experience vs. Transformation20:30 Focusing on the "Aspirant"22:00 Time Saved vs. Time Well Spent25:00 Experience design examples27:00 Novelty and social bonding31:15 Investment for time32:30 Turning experiences into change34:30 Service vs. Experience design37:30 Moving to transformations38:30 The power of intentionality40:45 Using reflection to add value43:30 Changing your identity44:45 Goal: Human flourishing47:30 What it means to flourish49:30 Satisfaction vs. improvement50:45 The drive for better51:30 Designing for transformation54:00 Transformative learning56:30 The Golf Coach story01:00:15 The new book release01:01:00 Key takeaway from Joe Pine01:02:45 Final thoughts --- [ 2. LINKS ] --- LinkedIn - https://www.linkedin.com/in/joepine/Website - https://strategichorizons.comBuy the book now --- [ 3. CIRCLE ] --- Join our private community for in-house service design professionals. ⁠https://servicedesignshow.com/circle[4. FIND THE SHOW ON]Youtube ~ https://go.servicedesignshow.com/246-youtubeSpotify ~ https://go.servicedesignshow.com/246-spotifyApple ~ https://go.servicedesignshow.com/246-appleSnipd ~ https://go.servicedesignshow.com/246-snipd

Do your descriptions fall flat?  Are your characters, locations, and NPCs just static items in time that never change?  In this episode I'll give players some tips for changing their character descriptions and for GMs to change NPC and place descriptions to improve their game.   #rpg #ttrpg #dnd #pathfinder #gmtips #playertips #tabletop #burnout #descriptions Resources: Crispy's Tavern, The Real Matt Mercer -  https://www.youtube.com/watch?v=FV-4HnJT_Rg Roll 4 Initiative - A Guide to Better Descriptions - https://www.youtube.com/watch?v=qhFmAW3KIYY Buy Me a Coffee! - ko-fi.com/taking20podcast www.taking20podcast.com  Instagram - https://www.instagram.com/taking20podcast  Facebook - https://www.facebook.com/taking20podcast  Bluesky - https://bsky.app/profile/taking20podcast.bsky.social 

Guest Suggestion Form: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://forms.gle/bnaeY3FpoFU9ZjA47⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/eCfijRu⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Order 'Build Don't Talk' (in Hindi) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/4wZISO0⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Our Whatsapp Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2J⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe To Our Other YouTube Channels:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@rajshamaniclips⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@RajShamani.Shorts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠(00:00) - Intro(2:51) - Metabolic Dysfunction(7:00) - What Is Insulin Resistance?(18:58) - Progression of Insulin Resistance(25:10) - Signs That You Are Insulin Resistant(32:40) - TOFI – The “Thin Outside, Fat Inside” Phenomenon(37:27) - Why Indians Store Most Fat in Visceral Areas(45:52) - Why Your Body Doesn't Need Carbohydrates(57:53) - The Ketogenic Diet(1:00:12) - Why Are Carbohydrates Such a Big Part of Our Diet If They Aren't Essential?(1:07:21) - Two Grains That Are Better Than Wheat(1:14:25) - What Is Type 3 Diabetes?(1:18:46) - What Is Type 4 Diabetes?(1:25:17) - The Three Big Rocks of Metabolic Health(1:32:49) - Focus on High-Protein Diets(1:35:46) - BTS(1:36:38) - OutroIn today's episode, we have Karan Sarin, author of Sick Nation, breaking down why India is facing a silent metabolic epidemic.The conversation goes deeper into the coming dementia crisis in India, insulin resistance as a hidden driver of PCOS, and why erectile dysfunction can be an early warning sign of metabolic damage. We also discuss how chronic stress quietly destroys metabolic health, veg vs non-veg diets from a metabolic lens, and the three most important levers to fix metabolic health.This episode is essential for anyone serious about long-term health, energy, and disease prevention.Subscribe for more such conversations.Follow Karan Sarin Here:Instagram: https://www.instagram.com/sweetreactions⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠About Raj ShamaniRaj Shamani is an Entrepreneur at heart that explains his expertise in Business Content Creation & Public Speaking. He has delivered 200+ speeches in 26+ countries. Besides that, Raj is also an Angel Investor interested in crazy minds who are creating a sensation in the Fintech, FMCG, & passion economy space.To Know More,Follow Raj Shamani On ⤵︎Instagram @RajShamani ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/rajshamani/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter @RajShamani ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/rajshamani⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook @ShamaniRaj ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/shamaniraj⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn - Raj Shamani ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/rajshamani/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠About Figuring OutFiguring Out Podcast is a Candid Conversations University where Raj Shamani brings raw conversations with the Top 1% in India.

In this episode, I'm joined by Nick Smoot to revisit several classic topics pulled from old articles he wrote on my website. We talk about whether static stretching is actually overrated, why progression still matters most for results, why not everyone needs to track their food, and how to think about cardio for fat loss.

Today we sit down with John Lack, Global Head of Sales Development at Airtable, to demystify the world of software sales as a profession. John breaks down the immense rewards of the industry—from earning six figures right out of college as a successful BDR to mastering the "autonomy, mastery, and purpose" of high-level tech sales. We explore why the BDR role is the most critical time in a career for building foundational grit and why 90% of AE struggles stem from poor front-end pipeline generation. John also shares his own unconventional journey, starting as a BDR at age 30 and scaling teams through massive growth phases at Oracle and MongoDB.

Alzheimer's disease isn't always the only health condition a person faces, so how does treating other diseases impact the progression of Alzheimer's? Researchers at the University of Arizona focused on four common health conditions – type two diabetes, hypertension, inflammation and dyslipidemia – which are known to increase the risk of developing Alzheimer's disease, and set out to investigate whether those diagnosed with Alzheimer's who received treatments for these four conditions also saw a delay in cognitive decline. Dr. Barb Bendlin joins the podcast to break down the findings from this research, as well as discuss the impact of personalized prevention strategies and combination therapies. Guest: Barbara Bendlin, PhD, professor, Division of Geriatrics and Gerontology, University of Wisconsin (UW) School of Medicine and Public Health, deputy director, UW Center for Health Disparities Research (CHDR) Show Notes Read the study, “Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline,” published by Alzheimer's & Dementia: Translational Research & Clinical Interventions on the Alzheimer's Association's website.  Read more about the study in the article “Four Key Pieces Managing Common Health Conditions Slows Alzheimer's Progression,” published on the National Alzheimer's Coordinating Center's website. Learn more about Dr. Bendlin from her profile on the UW Center for Health Disparities Research website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about and pre-order Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia, out June 2, 2026.

With Pastor Ron HammondsVisit cotr.com for more resources and sermons from GTCOTR.

Wayne Gretzky joins Neil Smith and Vic Morren for the very first NHL Wraparound episode. The Great One discusses Connor McDavid and the Edmonton Oilers' remarkable 22-3 turnaround in their last 25 games, Connor Bedard adapting after Brendan Smith's legal jaw-breaking hit, generational players from Bobby Orr through Sidney Crosby to Austin Matthews potentially reaching 800 goals, and Alex Ovechkin's chase of 894. Hear about playing at 147 pounds in Indianapolis, learning from Bobby Clarke to play behind the net because Phil Esposito could stand in the box, why today's players are better than the 80s, Gordie Howe's class when records get broken, Edmonton's four-line success with Paul Coffey coaching defense and Mattias Ekholm's impact, Kenny Holland's patience at 2-9 not trading for a goalie, and transitioning to TNT with Liam McHugh, Anson Carter, Henrik Lundqvist and Paul Bissonnette who studies more than people realize. Plus the only wraparound goal Gretz remembers, steak vs salmon game day meals, playing against Mark Messier in Edmonton, and teaching Coyotes kids to be pros on a $25M payroll.IN THIS EPISODE:[00:00] - Welcome: First NHL Wraparound guest ever, Wayne Gretzky, The Great One[01:00] - Only wraparound goal Gretz remembers: Vancouver 1997 hat trick third goal[02:00] - Darren Blake traveling secretary: ordered salmon in Vancouver, Gretz wanted steak[03:00] - Steak and potato game day meal entire career, never eaten salmon on game day[04:00] - That night scored three goals, last one wraparound against Cloutier[05:00] - Today's kids: Nathan MacKinnon, Connor McDavid, practice tricks, get excited[06:00] - Gretz not comfortable with skills competition: nothing to gain, everything to lose[07:00] - Connor Bedard jaw injury: Brendan Smith legal hit coming through middle[08:00] - Smith answering the bell: showed teammates toughness, respect for game[09:00] - First day Indianapolis training camp: 147 pounds, Blaine Stoughton "this is our savior"[10:00] - Playing against bigger competition entire career: 6 vs 10-year-olds, 11 vs 12-year-olds[11:00] - 14 playing against 20-year-olds, 16 playing against 20-year-olds, never big[12:00] - Learned to protect myself through years of bigger competition[13:00] - Age 14 junior B coach Dean Pappas: Phil Esposito greatest center[14:00] - Esposito 500 shots one year, middle of box on power play, nobody could move him[15:00] - Coach: go home watch Bobby Clarke, played out of corners more than behind net[16:00] - Started playing behind net and corners because of size, copying Bobby Clarke[17:00] - Couldn't stand in middle of box: would've been on rear end, guys knocked you over[18:00] - Generational player definition: combination of skill, talent, consistency, championships[19:00] - Gordie Howe retired, Bobby Orr retired, Guy Lafleur retired, Mike Bossy retired[20:00] - Along came Mario Lemieux, Mark Messier, Steve Yzerman, game survived[21:00] - Sidney Crosby and Alex Ovechkin: consistent every year, Crosby 37 having best year[22:00] - Both won championships, great for NHL, wonderful in communities[23:00] - Helping people less fortunate, helping kids who want to play hockey[24:00] - Not just on-ice, combination of ice, Stanley Cup, fitting into community[25:00] - Leon Draisaitl, Nathan MacKinnon, Mitch Marner, Austin Matthews, Connor McDavid next[26:00] - Great players, great for league, great in communities[27:00] - Never say we were better in 80s: these kids better than we were 40 years ago[28:00] - Progression: 20 years from now kids will be better than today, how NHL grows[29:00] - Impressed how kids handle themselves, play hard every night, show up competitive[30:00] - Winning Stanley Cup big part: MacKinnon and Makar won, Sidney won, Ovechkin

This podcast shows you how to fully recover from OCD.Each episode breaks down the exact techniques and nuances that stop rumination, reduce compulsions, and help you retrain your brain out of the OCD cycle. We cover every major OCD theme, including:Pure-O OCDRelationship OCDHarm OCDReal Event OCDSO-OCD / Sexuality OCDReligious / Scrupulosity OCDCleaning & Contamination OCDPhysical CompulsionsAll other OCD subtypesMy goal is simple: clear guidance that actually works, explained in a way that is calm, direct, and easy to apply immediately.You can fully recover from OCD. Don't give up — you're not stuck, and your brain can change.

Throughout the Old Testament, there was a progression of covenants with the Fathers of our Faith, leading up to our final covenant with Jesus.  Even though we don't think in terms of covenants much today in the Old Testament, a covenant, specifically a blood covenant, was the most powerful and binding agreement known to man. It was a permanent joining of two people, two families, or two groups of people. This is exactly how much God wants to be in covenant with us. 

Five articles from the January 2026 issue summarized in five minutes, with the addition of a brief editorial commentary. The 5-in-5 feature is designed to give readers an overview of articles that may pique their interest and encourage more detailed reading. It may also be used by busy readers who would prefer a brief audio summary in order to select the articles they want to read in full. The featured articles this month are: Risk Factors for Progression to Glenohumeral Arthritis After Arthroscopic Anterior Stabilization in a Young and High-Demand Population Characterizing the Transition Zone Between the Meniscotibial Ligament and the Medial Meniscus: A Hidden Trigger for Ramp Lesions Rates of Arthrofibrosis in Adolescent Patients After ACL Reconstruction Using Hamstring Autograft With or Without Lateral Extra-articular Tenodesis Long-term Outcomes After Hip Arthroscopy for Femoroacetabular Impingement Syndrome in Master Athletes: A Propensity-Matched Study With Mean 10-Year Follow-up Functional, Radiological, and Scapular Motion Evaluation of Surgical Versus Nonsurgical Treatment of Type 3 Acromioclavicular Dislocations: A Randomized Controlled Trial With 24 months' Follow-up Click here to read the articles.

Most fitness businesses don't fail because of effort.They fail because the system was never designed to scale.If you're still:• “Trying harder”• Tweaking ads without structure• Relying on motivation instead of infrastructure…this video will expose exactly why that approach breaks.Inside this breakdown, we dismantle the biggest lie in the fitness industry:

On episode 730 of the 40+ Fitness podcast, Coach Allan welcomes back Hilary Topper, an inspiring endurance athlete, coach, and author. Once a self-proclaimed non-athlete, Hilary Topper shares her extraordinary journey from lacing up her running shoes for the first time at age 48 to becoming a triathlon competitor and coach. Together, they dive into her new book, Unlocking the Triathlon: A Beginner's Guide to Competing in a Triathlon, providing a roadmap for anyone curious about trying a triathlon—especially if the idea has ever felt intimidating or out of reach. In this episode, you'll learn what a triathlon really entails, the different types and distances you can try, and how to take those crucial first steps, no matter your fitness level. Hilary Topper and Coach Allan cover practical advice on gear, training, and overcoming common fears, plus the importance of mindset, nutrition, and celebrating your personal progress. Whether you're looking for a new fitness challenge, want to shake up your routine, or simply enjoy stories of transformation and perseverance, this conversation is packed with expert tips and encouragement to help you unlock your full potential at any age. Time Stamps 05:39 Progression to Endurance Challenges 07:54 Multisport Options for Everyone 14:01 Running vs. Triathlon Costs 16:12 Wetsuits and Goggles Tips 17:48 Tech-Enhanced Swimming Gear Tips 21:36 Understanding Training Zones 25:38 Effort Zones Explained 27:48 Positive Self-Talk for Confidence

In this episode of the Black Belt Business Podcast, Easton Muay Thai Program Director Sean Madden joins Eliot to explain why Muay Thai programs in America need clear structure and progression. They discuss how Easton built a ranking and ascension model that improves safety, retention, and class quality while preserving the integrity of the art. A must-listen for any school owner running a striking program.   Watch or listen to the full podcast on our blog: https://www.easton.online/blog/ Visit https://www.easton.online to sign up for our mailing list!

10,000 – that's the magic number of steps often recommended for a healthy lifestyle. With recent research looking into whether that number is an accurate benchmark for health, could the number of steps taken per day have an impact on brain health and, specifically, cognitive decline? That's precisely what a new study from Harvard Medical School and Mass General Brigham sought to examine, looking at how physical activity, specifically step count, impacted cognitive decline for those living with Alzheimer's disease. Dr. Bri Breidenbach and Sarah Lose join the podcast to break down the results of this new study, as well as share what current research says about the effect of other kinds of physical activity, such as different intensity exercises, on the brain and Alzheimer's progression. Guests: Bri Breidenbach, PhD, scientist, exercise physiologist, Okonkwo Lab, and Sarah Lose, MS, research program manager, exercise physiologist, Okonkwo Lab, UW School of Medicine and Public Health   Show Notes Read the study, “Physical activity as a modifiable risk factor in preclinical Alzheimer's disease,” published by the journal Nature Medicine on their website. Learn more about Dr. Breidenbach and Sarah Lose's work on the Okonkwo Lab website. Read “Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK,” mentioned by Dr. Breidenbach at 12:01, on JAMA Neurology's website. Listen to Sarah Lose's previous episode, “Building the Brain: Finding the Cognitive Benefits of Physical Activity,” on our website. Learn more about physical activity and the six pillars of brain health on our website. Complete the Dementia Matters Feedback Survey to let us know what our show is doing well and how we can improve in the New Year! This anonymous survey is estimated to take about 5 minutes to complete and is open to all.   Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

This podcast shows you how to fully recover from OCD.Each episode breaks down the exact techniques and nuances that stop rumination, reduce compulsions, and help you retrain your brain out of the OCD cycle. We cover every major OCD theme, including:Pure-O OCDRelationship OCDHarm OCDReal Event OCDSO-OCD / Sexuality OCDReligious / Scrupulosity OCDCleaning & Contamination OCDPhysical CompulsionsAll other OCD subtypesMy goal is simple: clear guidance that actually works, explained in a way that is calm, direct, and easy to apply immediately.You can fully recover from OCD. Don't give up — you're not stuck, and your brain can change.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue: "The Natural Progression of Synkinesis" by Rail, Bhatia, Dragun, et al. Read the article for FREE: https://bit.ly/NaturalSynk Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

This podcast shows you how to fully recover from OCD.Each episode breaks down the exact techniques and nuances that stop rumination, reduce compulsions, and help you retrain your brain out of the OCD cycle. We cover every major OCD theme, including:Pure-O OCDRelationship OCDHarm OCDReal Event OCDSO-OCD / Sexuality OCDReligious / Scrupulosity OCDCleaning & Contamination OCDPhysical CompulsionsAll other OCD subtypesMy goal is simple: clear guidance that actually works, explained in a way that is calm, direct, and easy to apply immediately.You can fully recover from OCD. Don't give up — you're not stuck, and your brain can change.